Significats de acromegalic en anglès

Somatostatin analogs are an alternative treatment to pituitary surgery and radiotherapy in acromegalic patients.

Patients Nineteen acromegalic patients with active disease after unsuccessful neurosurgery and somatostatin analog therapy.

Our findings suggest that both insulin sensitivity and β-cell function are improved by tumor resection in acromegalic patients.

In conclusion, this study demonstrates the key role of RUNX2 gene overexpression in causing bone impairment in acromegalic patients.

This study aims to determine whether the detection of this mutation could impact on the management of acromegalic patients.

Mortality analysis has shown as many as 60 % of acromegalic patients die due to cardiovascular disease.

We aimed to elucidate the skeletal conditions of acromegalic patients by means of bone microarchitecture analysis and evaluation of MSCs osteogenic commitment.

Material and methods: We selected 68 consecutive acromegalic patients referred to our hospital during a 5-yr period.

Our results showed an abnormal microarchitecture and demonstrated that bone impairment in acromegalic patients is associated with the upregulation of RUNX2 expression.

This study aimed to evaluate dQT as an early predictor of ventricular tachyarrhythmia, as sudden cardiac death commonly occurs in acromegalic patients.

The aim of this study was to establish the existence of primary acromegalic cardiomyopathy different from the cardiovascular complications often associated with acromegaly.

Ingestion of glucose is known to induce suppression of GH secretion in normal subjects and this phenomenon is often absent in acromegalic patients.

Thirty-four acromegalic patients, referred to our non-invasive laboratory and divided into two groups on the basis of the presence of hypertension, underwent echocardiographic studies.

We think that a non-invasive, simple and inexpensive marker-measurement of dQT-as part of cardiac monitoring could be valuable for screening complications in acromegalic patients.

Results: In the study population, 21% of the 2392 acromegalic patients initially followed in 25 tertiary endocrinology centres were lost to follow-up.

Methods: Acromegalic patients were considered lost to follow-up if no new information had been entered in their hospital records during the previous 2 years.